Pharmaceutically active compounds

Abstract: The disclosed invention is compounds represented by the formula and pharmaceutically acceptable acid addition, basic addition and quarternary amine salts thereof and pharmaceutically acceptable solvates thereof, wherein each Z is independently tetiary butyl, phenyl, naphthyl or adamantyl; substituted phenyl, wherein the substituents are one or more of halogen, lower alkoxy, phenoxy, nitrile, nitro, phenyslsulfonyl, loweralkyl­ sulfonyl, oxazol-2-yl, lower alkanoyl, benzoyl, lower alkoxycarbonyl, lower alkyl, lower alkylthio, phenyl, phenylaminothiocarbonyl, or lower alkylaminothiocarbonyl; 4 or 6 membered unsubstituted or substituted heterocyclic ring containing at least one nitrogen with the remaining members of the ring being at least one carbon, and optionally sulfur or oxygen, wherein the substituents are one or more of carboxyl, hydroxymethyl, lower alkyl, loweralkylcarbonyl or aryl lower alkyl; X and Y are each independently a bond, -O-, each Q is independently a divalent substituted or unsubstituted, straigh or branched chain lower alkanediyl, lower alkanediyl-cycloalkaneidyl-lower alkanediyl, lower alkenediyl, lower alkynediyl, phenylene, dihydrofurandiyl, tetrahydrofurandiyl, tetrahydropyrandiyl, or, loweralkanediyl-­ tetrahydrofurandiyl-loweralkanediyl, wherein the substituents are one or more of hydroxy, epoxy, fluorine, chlorine, azide, or amino; W is a monovalent substituted or unsubstituted aryl group or a heterocyclic single or fused ring containing from 4 to 10 ring atoms, at least one hetero atom of which is a nitrogen atom and the remaining ring atoms being at least one carbon and optionally sulfur or oxygen, wherein the substituents are one or more of hydroxy, oxo amino, carbamoyl, carboxyl, nitrile, nitro, lower alkoxy carbonyl, halogen, sulfamyl, lower alkyl, lower alkylthio, lower alkoxy, hydroxyloweralkyl, lower alkoxycarbonylloweralkyl, amino loweralkyl, carboxy­ loweralkyl, guanidino, thioureido, lower alkylsulfonyl­ amino, aminocarbonylloweralkyl, allyloxycarbonylmethyl or carbamoyloxyloweralkyl; with the proviso that W cannot be substituted or unsubstituted isoxazolyl, and W′ is divalent W. The compounds have antiviral activity, antiinflammatory activity and are PAF inhibitors.

Description: This invention relates to compounds with pharmaceutical activity, i.e. antiviral, antiinflammatory and platelet activating factor inhibition, their pharmaceutically acceptable salts and solvates and pharmaceutical compositions containing the active compounds. Arildone, a compound represented by the formula is active in vitro against herpes virus and polio virus, but is only marginally active against rhinoviruses. Diana et al., J. Med. Chem. 28 , 748 (1985) prepared some alkyl-substituted isoxazole analogs of arildone in an attempt to prepare compounds with broad spectrum activity against picornaviruses. Some of the compounds were active against both rhinovirus type 2 and poliovirus type 2. However, there is no indication that any of the Diana et al. compounds have activity as antiinflammatories or as platelet activating factor inhibitors. Many of the compounds of this invention possess such activity. The compounds of this invention are represented by the following structural formula I Z-X-Q-Y-W I pharmaceutically acceptable acid addition, basic addition, and quaternary amine salts thereof and pharmaceutically acceptable solvates thereof, wherein each Z is independently tertiary butyl, phenyl, naphthyl or adamantanyl; substituted phenyl, wherein the substituents are one or more of halogen, lower alkoxy, phenoxy, nitrile, nitro, phenylsulfonyl, loweralkylsulfonyl, oxazol-2-yl, lower alkanoyl, benzoyl, lower alkoxycarbonyl, lower alkyl, phenyl, lower alkylthio, phenylaminothiocarbonyl, or lower alkylaminothiocarbonyl; 4 to 6 membered unsubstituted or substituted heterocyclic ring containing at least one nitrogen in the ring with the remaining members of the ring being at least one carbon, and optionally sulfur or oxygen wherein the substituents are one or more of -COOH, -CH₂OH, lower alkyl, loweralkylcarbonyl, or aryl lower alkyl; X and Y are each independently a bond, -O-, -S-, -SO₂-, each Q is independently a divalent substituted or unsubstituted, straight or branched chain, loweralkanediyl-cycloalkanediyl-loweralkanediyl, lower alkynediyl, phenylene, dihydrofurandiyl, tetrahydrofurandiyl, tetrahydropyrandiyl, loweralkanediyl-tetrahydrofurandiyl-loweralkanediyl wherein the substituents are one or more of hydroxy, epoxy, fluorine, chlorine, azide, or amino; W is a monovalent substituted or unsubstituted aryl group or a heterocyclic single or fused ring containing from 4 to 10 ring atoms, at least one hetero atom of which is a nitrogen atom and the remaining ring atoms being at least one carbon and optionally sulfur or oxygen, wherein the substituents are one or more of hydroxy, oxo, amino, carbamoyl, carboxyl, nitrile, nitro, lower alkyl, loweralkoxycarbonyl, halogen, sulfamyl, loweralkoxycarbonylloweralkyl, loweralkythio, lower alkoxy, hydroxy loweralkyl, amino loweralkyl, carboxy loweralkyl, guanidino, thioureido, lower alkyl sulfonylamino, aminocarbonylloweralkyl, allyloxycarbonylmethyl or carbamoyloxyloweralkyl, with the proviso that W cannot be substituted or unsubstituted isoxazolyl. Compounds of formula II with structure Z-X-Q-Y-W'-Y-Q-X-Z in which W' is divalent W form the subject of a separate invention. The invention also includes pharmaceutical compositions containing pharmaceutically effective amounts of a compound of formula I or formula II as well as method of treating virus infections, inflammation and inhibiting platelet activating factor using the appropriate pharmaceutical compositions. As used herein "lower alkyl" alone or in combined form, e.g. "lower alkoxy" or "loweralkanediyl", means straight or branched chain alkyl groups of from 1 to 10 carbon atoms, e.g. methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl, neopentyl, hexyl and the like. The heterocyclics at Z and W are monovalently bonded to X and Y respectively by a hetero atom, preferably nitrogen, or by a carbon atom. The heterocyclics at W' preferably have two nitrogens, each of which is bonded to a separate -Y-Q-X-Z moiety. Heterocyclic groups within the scope of this invention for Z are, for example, imidazolyl (such as imidazol-1-yl, imidazol-2-yl, imidazol-4-yl, and imidazol-5-yl), dihydrothiazolyl (such as 4, 5-dihydrothiazol-2-yl), tetrazol (such as tetrazol-5-yl, tetrazol-1-yl, and tetrazol-2-yl), pyridinyl (such as pyridin-2-yl), triazolyl (such as 1, 2, 4-triazol-1-yl), tetrahydro-pyrimidinyl (such as 1, 2, 3, 4-tetrahydro-pyrimidin-1-yl), dihydro-oxazolyl (such as 4, 5-dihydro-oxazol-2-yl), pyrrolidinyl (such as pyrrolidin-1-yl), pyrazolyl (such as pyrazol-1-yl and pyrazol-2-yl), morpholinyl, and azetidinyl. All possible attachment positions of the above heterocyclic groups are within the scope of this invention. Heterocyclic groups within the scope of this invention for W are, for example, all those listed above for Z and, in addition, fused ring compounds, for example benzamidazolyl (such as benzamidaol-1-yl and benzamidazol-2-yl), naphthyridinyl (such as naphthyridin-l-yl), purine (such as purine-9-yl and purine-7-yl), and quinolinyl. Heterocyclic groups within the scope of this invention for W′ are all those listed above for Z and W, but being divalent. For example, if W′ were tetrahydro-pyrimidinyl, it could be 1, 2, 3, 4-tetrahydro-pyrimidin-1, 3-diyl. W′ as a bernzamidazolyl group could be, for example benzamidazol-1,3diyl. In other words, to obtain a possible W′ group from the groups listed for Z and W, the "yl" suffix in the Z and W radical is replaced by "diyl". "Aryl" as used herein refers to phenyl and naphthyl. "Halogen" as used herein means chlorine, fluorine, bromine or iodine with chlorine or fluorine preferred. "Cycloalkane", alone or in combined form, means a 4, 5, 6 or 7 membered saturated carbocylic ring. "Lower alkene", alone or in combined form, means a 2 to 10 carbon branched or straight chain alkene group. "Lower alkyne", alone or in combined form, means a 2-10 carbon branched or straight chain alkyne group. "Pharmaceutically acceptable salts" as used herein means acid addition salts formed from mineral acids such as hydrochloric, hydrobromic, phosphoric or sulfuric acids, or formed from organic carboxylic or sulfonic acids such as trifluoracetic, para-toluene, sulfonic, maleic, acetic, citric, oxalic, succinic, benzoic, tartaric, fumaric, mandelic, ascorbic and malic acids, or quaternary salts prepared from such organic halides as methyl iodide, ethyl idodide, benzyl chloride and the like, although all pharmaceutically acceptable quaternary salts are contemplated. Basic addition salts are also within the scope of this invention. The above salts are made by conventional means in the art, e.g. reaction of the compound with the appropriate acid, organic halide, or base. The preferred salt is the hydrochloride salt. "Hydroxy protecting group" as used herein means any known hydroxy protecting group which is removed by conventional reactions which do not adversely affect the compounds produced. Typical suitable hydroxy protecting groups are t-butyldimethysilyl (TBDMS) or tetrahydro-pyranyl. The compounds of this invention have been found to be active against ether-resistant RNA viruses, i.e. picornaviruses which includes enteroviruses and rhinoviruses. The enteroviruses include poliovirus, coxsackieviruses and echoviruses. Rhinoviruses include those viruses associated with the common cold and certain other respiratory ailments. Over one hundred serotypes are identified. Although the compounds of this invention are not active against all the rhinoviruses, they are active against a large number of them including rhinovirus 2. The compounds of this invention are also active against the enteroviruses such as poliovirus 2, coxsackieviruses A and B3, ECHO and hepatitis A. In addition, the compounds of this invention are active against certain DNA viruses such as herpesvirus and cytomegalovirus. Thus, they showed activity when tested in vitro activity assays, i.e. plaque reduction assays which measure the ability of synthetic cojpounds to neutralize virus infectivity, e.g. picornavirus infectivity. In tests against coxsackievirus 3, the IC₅₀ values of the tested compounds of this invention varied from about 0.7 microgram/ml to about 1.4 microgram/ml. The IC₅₀ value in all antiviral tests is the concentration of test compound in micrograms per milliliter which results in a 50% decrease in plaque forming units compared to a non-treated control. In a modified standard test, i.e. wherein the virus and test compound are mixed and incubated prior to overlaying with an agar medium active compounds of this invention had IC₅₀s of from about 6.0 to about 37.3 against poliovirus 2, about 8.5 to about 39.5 against human rhinovirus 14 and about 2.4 to 5.0 against cosackievirus B3. The standard test involves overlaying HeLa cells with agar medium containing measured concentrations of the test compound following virus absorption, then incubating for 72 hours. The resulting plaques are stained, visualized and measured to determine virus growth inhibition as evidenced by plaque reduction when compared to a control. The modified standard test is considered more sensitive because of its ability to discriminate more clearly the virus growth neutralizing effects between compounds whose IC₅₀s are very close according to the standard test. Of the antiviral compounds within the scope of formulas I and II, those which form water soluble acid addition salts are orally absorbable, show good tissue levels and serum stability. The preferred antiviral compounds of this invention are those represented by the following formula III Z¹-X¹-Q¹-W¹ III and pharmaceutically acceptable acid addition salts thereof, wherein Q¹ is lower alkynediyl of 6, 7 or 8 carbon atoms; and all possible isomers of methylcyclohexylmethyl, W¹ is unsubstituted or substituted imidazo-1-yl, purin-9-yl or imidazo-2-yl, wherein said substituents are one or more of loweralkyl, hydroxy loweralkyl, nitro, lower alkoxycarbonyl, carboxymethyl, aminocarbonylmethyl; X¹ is -O-, and Z¹ is The preferred acid addition salt is the hydrochloride. Certain compounds of this invention have been found to display activity in animal models of inflammation, Thus, in a reverse passive Arthus reaction in rats, the compounds were orally active when administered at dosages of from 25 to 100 mg/kg and in the adjuvant induced arthritis test in rats were orally active. The reverse passive Arthus test evaluates test compounds for activity against an immune complex, cell-mediated inflammatory reaction. In the performance of the test, rats previously fasted for 24 hours are dosed with the test compound, then after one hour are lightly anesthesized and injected (iv) with 1.0 mg bovine serum albumin (BSA) in 0.1 ml sterile saline. Then the rats are injected intrapleurally with 0.1 ml sterile saline containing 100 micrograms of antibody protein to bovine serum albumin. Four hours after challenge, the rats are sacrificed and pleural cavity transudate is removed and the volume recorded. The pleural cavity is then washed with 3 ml of cold saline and the wash is removed and added to the original transudate. After being treated with an anticlot agent or EDTA, the transudate is cooled on ice and the volumes of the test transudate and control transudate are adjusted to 5.5 ml with saline and their white blood cell counts are determined on a Z1 Coulter Counter. The differences between transudate volume (a measure of edema) and total white blood cell counts (a measure of neutrophil accumulation) between the controls and drug treated groups is a measure of the drugs antiinflammatory activity. These effects are stated as a percent inhibition or reduction in neutrophil count and transudate volume. The adjuvant induced arthritis test in rats evaluates the effect of a drug on an immune mediated model of chronic inflammation. In the performance of the test, animals (rats) are dosed orally with drugs at a volume of 1 ml per 100 grams of body weight. The drug concentration is varied for different test dosages. The rats are dosed with the test compound one hour prior to sensitization with an adjuvant. The adjuvant used in this test model is heat killed mixed M. tuberculosis homogenized in paraffin oil. Controls are given the methylcellulose vehicle alone. The adjuvant is injected into the subplantar region of the left hind paw, immediately thereafter the volumes of the left and right hind paws are measured with a plethysmograph. Injected paw volumes are measured after 24 hours and then 21 days later. The contralateral hind paw is only measured 21 days later. The differences in paw volumes between the first and last measurements are related to the degree of inflammation. Antiinflammatory drugs reduce these differences. The compounds of this invention which exhibit antiinflammatory activity are those with an imidazo-1-yl or lower alkyl substituted imidazo-1-yl at the W position of formula I. Certain of the compounds of this invention have been found to display platelet-activating factor (PAF) antagonism. PAF has been shown to be involved in the pathophysiology of various allergic and inflammatory diseases. It is an important mediator of such processes as platelet aggregation, smooth muscle contraction, especially lung tissue, vascular permeability and neutrophil activation. Furthermore, recent evidence implicates PAF as the underlying factor involved in airway hyperreactivity. As such, PAF is implicated in diseases such as asthma (bronchoconstriction and pulmonary edema) and inflammation. Antagonists or inhibitors of PAF, such as the compounds of this invention, would therefore be of use whenever PAF is a factor in the disease or disorder. This includes allergic diseases such as asthma, adult respiratory distress syndrome and urticaria, and inflammatory diseases such as rheumatoid arthritis and osteoarthritis. In the in vivo PAF Induced Bronchiospasm in Guinea Pigs, compounds of this invention exhibit IC₅₀ values of from about 3 to about 60 mg per kg. In the in vitro PAF Antagonism Assay, compounds of this invention show an inhibition of PAF activity from about 20 to 100% at varying concentrations. The PAF Induced Bronchiospasm in Guinea Pigs assay is conducted as follows: Non-sensitized guinea pigs were fasted overnight, and the following morning were anesthetized with 0.9 ml/kg i.p. of dialurethane (0.1 gm/ml of diallylbarbituric acid, 0.4 gm/ml of ethylurea and 0.4 gm/ml of methane). The trachea was cannulated and the animals were ventilated by a Harvard rodent respirator at 55 strokes/min with a stroke volume of 4 ml. A side arm to the tracheal cannula was connected to a Harvard pressure transducer to obtain a continuous measure of intratracheal pressure, which was measured on a Harvard polygraph. The jugular vein was cannulated for the administration of compounds. The animals were challenged i.v. with PAF (0.4 µg/kg in isotonic saline containing 0.25% BSA) and the peak increase in inflation pressure that occurred within 5 min. after challenge was recorded. Test compounds were administered either orally (2 hours prior to PAF as a suspension in 0.4% methyl cellulose vehicle) or intravenously (10 minutes prior to PAF as a solution in DMSO). The effect of compounds on the bronchoispasm is expressed as a percent inhibition of the peak increase in intratracheal pressure compared to the peak increase in the control group. The IC₅₀ is the dosage in mg/kg required to obtain a 50% inhibition. The in vitro PAF Antagonism Assay as conducted as follows: Platelet-activating factor (PAF) causes aggregation of platelets in a receptor-mediated mechanism. Therefore, PAF-inducced platelet aggregation provides a simple and convenient assay to screen compounds for PAF antagonism. Preparation of platelet-rich plasma (PRP) Human blood (50 ml) is collected from healthy male donors in an anticoagulant solution (5 ml) containing sodium citrate (3.8%) and dextrose (2%). Blood is centrifuged at 110 X g for 15 min. and the supernatant (PRP) carefully transferred into a polypropylene tube. Platelet-poor-plasma (PPP) is prepared by centrifuging PRP at 12,000 X g for 2 min. (Beckman Microfuge B). PRP is used within 3 hours of drawing the blood. Platelet Aggregation Assay When an aggregating agent such as PAF is added to PRP, platelets aggregate. An aggregometer quantifies this aggregation by measuring and comparing light (infra-red) transmission through PPP and PRP. The aggregation assays performed on the compounds of this invention are performed using a dual-channel aggregometer (Model 440, Chrono-Log Corp., Havertown, PA). PRP (0.45 ml) in aggregometer curettes is continually stirred (37°C). Solutions of test compounds or vehicle are added to the PRP, and after incubation for 2 min., 10-15 µl aliquots of PAF solution are added to achieve a final concentration of 1-5 X 10⁻⁸M. Incubations are continued until the increase in light transmission reaches a maximum (usually 2 min.). Values for inhibition are calculated by comparing maximal aggregation obtained in the absence and the presence of the test compound and expresed as percent inhibition. For each experiment, a standard PAF antagonist such as alprazolam is used as a positive internal control. Preferred PAF antagonist compounds of this invention are represented by the following formula V: Z²-X²-Q²-Y²-W² V pharmaceutically acceptable acid addition salts or quaternary amine salts thereof, wherein Z² is phenyl; substituted phenyl wherein the substituents are independently one or more of halogen, loweralkylthio, loweralkylsulfonyl, lower alkoxy, oxazol-2-yl, phenoxy; imidazol-1-yl; lower alkyl substituted imidazol-1-yl; or tert-butyl; X² is a bond, -O-, -S-, or -SO₂-; Q² is lower alkanediyl of 5, 6 or 7 carbon atoms optionally substituted by -OH; loweralkynediyl of 6-8 carbon atoms; or methylcyclohexylmethyl; Y² is a bond, -S- or -SO₂-; and W² is imidazol-1-yl; substituted imidazol-1-yl wherein the substituents are independently one or more of loweralkyl, hydroxy loweralkyl, aminoloweralkyl and lower alkoxycarbonyl; imidazol-2-yl; imidazol-4-yl; imidazol-5-yl; substituted imidazol-2-yl, -4-yl or -5-yl, wherein the substituents are independently one or more of lower alkyl, and allyloxycarbonylmethyl; pyrrolidin-1-yl; benzimidazol-1-yl; 1,4 dihydro-4-oxo-7-methyl-1,8-3-carboxyl-naphthyridin-1-yl; purin-9-yl; pyridin-2-yl; pyrazol-1-yl; or benzimidazol-2-yl. The most preferred compounds having PAF activity are represented by the following formula VI Z³-X³-Q³-W³ and pharmaceutically acceptable acid addition or quaternary salts thereof, wherein Z³ is X³ is -S-, -O-, or Q³ is lower alkanediyl of 5, 6 or 7 carbon atoms optionally substituted by -OH; W³ is and R⁴ is hydrogen, loweralkyl or hydroxy loweralkyl; R⁵ is lower alkyl; R⁶ and R⁷ are independently one or more of hydrogen, loweralkyl, amino loweralkyl or nitro. The compounds of this invention are conventionally formulated for oral, parenteral, topical and transdermal use, oral is preferred. This invention includes within its scope pharmaceutical compositions comprising the compounds of this invention in admixture with a pharmaceutically acceptable carrier therefor. In addition, the present invention also includes the use of the compounds of formula I for preparing pharmaceutical compositions useful for treating viral infections or inflammation, or for inhibiting platelet activating factor. In the foregoing compositions, the active compounds of this invention can be used alone as the sole active antiviral agent, sole active antiinflammatory agent or sole active PAF antagonist, or in combination with other therapeutic agents. For the preferred oral administration, the compounds of this invention are typically formulated in the form of tablets, capsules, elixirs, solutions, suspensions and the like preferably solutions. For parenteral administration, they may be formulated into solutions or suspensions. Topical formulations such as lotions, creams ointments sprays and mechanical delivery devices, e.g. transdermal can also be made with the compounds of this invention. Typical pharmaceutically acceptable carriers for use in the formulations described above are exemplified by: sugars such as lactose, startches such as corn starch, cellulose and derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and methyl cellulose; and other carriers well known in the art. The compositions may also contain preservatives, aerosol propellants and coloring, thickening, suspending, dispensing, emulsifying, wetting, stabilizing and buffering agents. The dosage of the compounds of this invention which is administered is dependent, in the judgment of the attending clinician, upon a variety of factors, e.g. the age and weight of the individual being treated, the mode of administration, the potency of the administered compound, the indication for which the drug is administered and the severity of the ailment being treated. Typically, the dosage administered per day for treating viral infections will be oral administration of from about 1 mg/kg to about 75 mg/kg daily in single or divided doses, with about 1-25 mg/kg preferred. The dosage for treating inflammation is about 25 mg to about 2 gm administered daily in divided doses, with the preferred range being about 25 to about 100 mg. In order to achieve PAF antagonism, oral administration daily in single or divided doses of about 2.5 mg/kg to about 50 mg/kg can be used, preferably about 2.5 mg/kg to about 25 mg/kg. Intravenous administration can be about 0.5 mg/kg to about 10 mg/kg per day with 0.5 mg/kg to about 5 mg/kg preferred. The compounds of this invention are prepared by the following methods: (A) to produce a compound of formula I, reacting a compound of the formula Z-X-Q'-L¹ wherein Z and X are as defined previously, Q' is the same as Q defined previously, or, provided Q in formula I is to contain at least one of the group wherein each R is independently hydrogen or lower alkyl, Q' may also be the same as Q defined above minus at least one of the groups and L¹ is a leaving group, with a compound having the formula L²-Y'-W'' where L² is a leaving group, W'' is as defined for W in formula I, or a tautomer thereof, and Y' is the same Y defined in formula I, or, provided Q in formula I is to contain at least one of the groups wherein each R is independently hydrogen or lower alkyl, Y' may also be the same as Y defined in formula I plus at least one of the groups or (B) to produce a compound of formula I, at least one compound of the formula Z-X-Q'-L¹ wherein Z, X, Q' and L¹ are as defined previously is reacted with a compound of the formula L³-Y'-W'''-Y'-L⁴ wherein L³ and L⁴ are leaving groups each Y' is independently as defined above, and W''' is divalent W' as defined above, or (C) to produce a compound of formula I wherein Z and W are the same and X and Y are the same, reacting a compound of the formula L²-Y'-W'' wherein Y' and W'' are as defined previously and L² is a leaving group, with a compound of the formula L⁵-Q''-L⁶ wherein L⁵ and L⁶ are leaving groups and Q'' is divalent Q' as defined above, wherein in the above processes, any reactive groups are protected if necessary or desired, the above processes followed, if necessary or desired. by (i) removal of any protecting groups, (ii) conversion of a compound so produced to another compound of formula I, (iii) if more than one compound of formula I is produced, separation of the compounds so produced, or (iv) conversion of any of the compounds so produced to an acid addition, basic addition, or quaternary amine salt or pharmaceutically acceptable solvate thereof. In process (A), L¹ is preferably bromine or most preferably iodine and L² is a preferably alkali metal such as sodium, potassium or cesium. The reaction takes place at temperatures of from about -20°C to 60°C in an inert organic solvent such as dimethylsulfoxide (DMSO), dimethylformamide (DMF) or tetrahydrofuran (THF). In most cases the final compounds can be converted to water-soluble acid addition or quaternary salts by conventional reactions, e.g., with hydrochloric acid or a quaternizing agent such as methyl sulfonic acid. The starting compounds Z-X-Q'-L¹ wherein L¹ is halogen (Hal) are prepared by the following reaction: wherein Z, X and Q' are as defined above. The reaction takes place in the presence of an acid scavenger such as K₂CO₃ or organic bases such as collidine and also Hunigs base. The preferred Hal group is iodine although bromine can also be used. The compound Hal-Q'-Hal wherein Hal is iodine can be prepared by reacting Br-Q'-Br with sodium iodide except when Q is -CH₂- or -CH₂-CH₂-. Alternatively ZXQ'-I can be prepared by reacting ZXH with Br-Q'-Br to obtain ZXQ'Br, then reacting ZXQ′Br with sodium iodide to obtain Z-X-Q′-I. Or for compounds when Q′ is -CH₂- or -C₂H₄-, Z-X-Q′-I can be prepared by reacting the corresponding mono or dihydric alcohol with HI. When W is a nitrogen containing heterocyclic moiety, the processes described above result in the W moiety being substituted at a nitrogen atom of the heterocyclic ring, unless the nitrogen atom is protected. In order to make a compound wherein the heterocyclic is substituted at a ring carbon, it is necessary to protect the nitrogen with a group which is easily removed after the C-substitution is carried out and is not removed during the C-substitution reaction, e.g., the trityl group. Thus, for example, in the preparation of a 2-substituted imidazole, the following reaction scheme is followed: wherein Q, Q′, Z and X are as defined above. In this case the methyl group on the imidazo ring becomes part of Q in the compound produced. In process (B) to make a compound of formula II, the W' moiety should have two ring carbons initially substituted with trimethylsilyloxy groups. When the reaction with Z-X-Q'-I is conducted, the resulting product is a disubstituted W' moiety as shown in the following reaction in which the trimethylsilyloxy substituted compound is illustrated as a pyrimidine. The reaction is carried out at room temperature. In process (B) if an excess of the compound Z-X-Q'-L¹ is used, the product will primarily be of formula II. However, if only small amounts of the compound Z-X-Q'-L¹ is used, products of formulas I and II will be produced. The reaction conditions are the same as in process (A). Process C, which produces compounds of formula I wherein Z and W are the same and X and Y are the same, is carried out under the same reaction conditions as process (A). The preparation of compounds wherein Q is an unsaturated chain, i.e. an alkynediyl is illustrated in the following reaction: wherein R⁸ is lower alkyl of 2 to 4 carbons and R' is lower alkynyl of 3 carbons, Y is a bond, Pr is a hydroxy protecting group and hal is bromine or iodine. The preparation of compounds in which Q is an alkyl having a cycloalkane in the chain is illustrated by the following reaction: wherein hal is bromine or iodine and Z, X, Y and W are as defined above for formula I. A compound of formula I or II can be converted to a different compound of formula I or II, respectively, by standard techniques well known in the art. Such conversion techniques are illustrated in the examples. In general preparing the compounds of this invention involves relatively simple procedures as illustrated by the many Examples which appear later in this text. The following Table I shows compounds of formula I prepared by the processes described above and in Examples 1 -4. Table II shows compounds, related to those of formula I, prepared by the processes described in Examples 5-21. Table III shows additional compounds of formula I which can be prepared by following the procedures of the Examples which follow by substituting the appropriate starting materials. The starting materials for use in the preparation of the compounds of this invention are either commercially available or are prepared by conventional means known in the art. The following examples illustrate the invention. Fast atom bombardment (FAB) mass spectra (MS) were run on a Finnigan MAT 312 double focussing mass spectrometer, operating at an accelerating voltage of 3 kV. The MS samples were ionized by bombardment with xenon atoms produced by a saddle field ion source from Ion Tech operating with a tube current of 2 mA at an energy of 6 KeV. The proton nuclear magnetic resonance (H¹-NMR) spectra were recorded at 200 MHz on a Varian XL-200 spectronometer; all chemical shift values δ are reported in ppm downfield from tetramethylsilane. EXAMPLE 1 Trans 1-[(2-chloro-4-methoxyphenoxy)methyl]4-[(1-imidazolyl)methyl]cyclohexane (a) Add 14.5 gm. of trans 1,4-bis hydroxymethyl cyclohexane to 250 ml. methylene chloride and add 20 ml. methanesulfonyl chloride, cool to 0°C and slowly add 36 ml. triethylamine over a period of one hour. Remove the solvent, extract with water, filter and wash with methanol to obtain trans 1,4-bis mesylate methyl cyclohexane. (b) Add 30 gms. of the mesylate prepared in step (a) to 300 ml. methylethyl ketone (MEK), then add 90 gm. sodium iodide and reflux for about 30 minutes. Remove the solvent and extract with methylene chloride to yield trans 1,4-bis iodomethyl cyclohexane. (c) Add 3 gms. of 2-chloro-4-methoxyphenol, 15 gms. of the diodo compound prepared in step (b), 100 ml. water, 100 ml. methylene chloride in a reaction flask, add 0.5 gm (n-butyl) ammonium sulfate and 25 ml 50% aqeuous NaOH. Elute on a silica column. A mixture of mono and bis ether results as evidenced by NMR. Add the resulting mixture to 3 gm. sodium imidazole in 20 ml. DMF. Stir at room temperature for about 48 hours. Remove the solvent and elute on a silica column with 100% methylene chloride then 5% methanol to yield the title compound. Prepare the hydrochloride salt by reaction with 0.1N HCl. FAB-MS: m/z 335 (M⁺) HCl salt, H¹-NMR-200 mHz, δ H (CDCl₃), 0.9-1.30 (4H,m), 1.6-2.1 (6H,m), 3.75 (3H,s), 3.77 (2H,d,J 6Hz), 4.2 (2H,d,J 6Hz), 6.7-7.0 (3H,m), 7.14 (1H,s), 7.43 (1H,s), 9.55 (1H,s). EXAMPLE 2 1-(9,9-dimethyl-dec-7-ynyl)-imidazole (a) Add 5 ml. freshly distilled THF and 413 mg. 3,3-dimethyl-1-butyne to a dry reaction flask, cool to -78°C then add 2.01 ml. n-butyl lithium (2.5M in hexane), stir about 30 minutes at -78°C, transfer into 3 ml. THF and 4.9 gm. 1,6-dibromo hexane at 0°C, stir 6 hours and add 2 ml. dry DMSO to form a precipitate. Wash with water, in methylene chloride. Elute through a short bed of silica with hexane to remove polar material giving a mixture of 1,6-dibromo hexane and 1 bromo-(9,9-dimethyl-dec-7-yne. (b) Stir overnight at room temperature 4.73 gm. of the mixture prepared in step (a), 5 ml. DMF and 2.1 gm. sodium imidazole, in a reaction flask. Add methylene chloride, wash with water, then brine and dry over sodium sulfate. Elute on a coarse silica column with methylene chloride, then 2% methanol/methylene chloride. Combine fractions containing product and chromatograph on a coarse silica column with 25% ethylacetate/methylene chloride, then 35% ethylacetate/methylene chloride to isolate the title compound. Prepare the hydrochloride salt by reaction with about 1.1 eq. of 0.1N HCl. EXAMPLE 3 1-[6-(2-chloro-4-methoxyphenoxy)-hex-2-ynyl]imidazole (a) Add 30 ml. THF and 10 ml. DMSO to a reaction flask and cool to -78°C. Add 7.4 ml. n-butyl lithium (2.5M/hexane), stir for five minutes and add 2.6 gms. of tetrahydropyran protected propargyl alcohol and warm to room temperature. Stir 5 minutes and add 3 gms. of 1-(2-chloro-4-methoxyphenoxy)propyl-3-bromide resulting in a slightly exothermic reaction. Stir for about 1.5 hours. Remove the THF by vacuum and partition with water/methylene chloride. Elute the methylene chloride residue on a silica column with 25% methylene chloride/hexane then 50/50 methylene chloride/hexane. Add the resulting product to 50/25/25 THF/H₂O/CH₃OH and add 1 gm. para toluene sulfonic acid. Stir overnight, remove THF/methanol, partition with 5% NaHCO₃/CH₂Cl₂ then with water/methylene chloride. Remove the CH₂Cl₂ to obtain the desired product, 1-hydroxy-6-(2-chloro-4-methoxyphenoxy)hex-2-yne. (b) Add 25 ml. thionyl chloride to 1.17 gms. of the compound prepared in step (a) and reflux for 1 hour. Remove the thionyl chloride. Add 25 ml. DMF and 3 gms. sodium imidazole and stir overnight. Remove the DMF and partition with H₂O/CH₂Cl₂. Elute on a silica column with 100% CH₂Cl₂ then 100% ethylacetate to obtain the title compound. Prepare the hydrochloride salt by reaction with about 1 eq. of 0.1N HCl. FAB-MS: m/z 305 HCl salt, H¹-NMR, 200 mHz, δ H(CDCl₂), 2.05 (2H,m), 2.55 (2H,m), 3.78 (3H,s), 4.08 (2H,t,J 5Kz), 5.20 (2H,m), 6.7-7.0 (3H,m), 7.30 (1H,s), 7.38 (1H,s), 9.6 (1H,s). EXAMPLE 4 1-(8-phenyl-oct-7-ynyl)imidazole (a) Prepare 6-phenylethynylhexyl-1-bromide by adding 1.07 ml phenylacetylene to 10 ml of THF in a reaction flask, cool to -78°C then add 3.9 ml n-BuLi (2.5 molar in hexane), stir 5 minutes, warm to 0°C and add 45 ml of 1,6-dibromohexane and 5 mol of dry DMSO. Stir at room temperature for 1.5 hours, remove solvent and treat with methylene chloride and water to recover the product. (b) Stir for 48 hours at room temperature in a reaction flask, 1.65 gms of the product of step (a) and 1.68 gm sodium imidazole in 5 ml DMF. Remover the resulting title compound by treating with methylene chloride, washing with water and drying over sodium sulfate. Then elute on a coarse silica column with 100% methylene chloride followed by 2% CH₃OH/CH₂Cl₂ to yield the title compound. Prepare the hydrochloride salt by reaction with 0.1N HCl. MS: m/z 253 (M⁺) HCl salt. EXAMPLE 5 1-[6-(2-chloro-4-methoxyphenoxy)hexyl]imidazole Add 200 mg. 6-(2-chloro-4-methoxyphenoxy)hexyl-1-bromide in 1.5 ml of dimethyl formamide (DMF) to 180 mg sodium imidazole in a reaction vial at room temperature, stir 2 hours then add 20 mg sodium iodide, stir overnight. Add methylene chloride, wash with water then brine, elute on a coarse silica column with methylene chloride then a mixture of 50% ethylacetate and methylene chloride (v/v) to isolate the title compound. EXAMPLE 6 2-{[6-(2-chloro-4-methoxyphenoxy)hexyl]thio} -4,5-dihydrothiazol-4-one (a) Reflux about 500 mg sodium iodide in 10 ml of acetone with 350 mg. 6-(2-chloro-4-methoxyphenoxy)-hexyl-1-bromide for 5 to 10 minutes, remove the acetone by bubbling nitrogen through the reaction mixture, add methylene chloride, wash with water, then brine and dry over sodium sulfate to obtain 6-(2-chloro-4-methoxyphenoxy)hexyl-1-iodide. (b) Add 3 grams of 6-(2-chloro-4-methoxyphenoxy)hexyl-1-iodide in 10 ml acetonitrile to 1.2 g rhodanine and 20 g cesium carbonate. Stir overnight, then remove the acetonitrile, add methylene chloride and wash with water then brine and dry over sodium sulfate. Elute on a coarse silica column with methylene chloride followed by 5% ethylacetate/methylene chloride and finally 10% ethylacetate/methylene chloride to yield the title compound isolation. EXAMPLE 7 5-{[6-(2-chloro-4-methoxyphenoxy) hexyl]thio}-1-methyltetrazole Reflux 350 mg. 6-(2-chloro-4-methoxyphenoxy) hexyl-1-bromide with 10 ml of acetone and about 500 mg. sodium iodide for five to ten minutes, remove the acetone by bubbling nitrogen through the reaction mixture, add methylene chloride, wash with water, then brine and dry over sodium sulfate to obtain 6-(2-chloro-4-methoxyphenoxy)hexyl-1-iodide. Add 133 mg of 5-mercapto-1-methyltetrazole, 268 mg. cesium carbonate and 3 ml acetonitrile to the iodide product, stir overnight, add methylene chloride and wash with water, sodium carbonate, water, then brine and dry over sodium sulfate. Remove the solvent and recover the title compound as crystals. EXAMPLE 8 2-{[6-(2-chloro-4-methoxyphenoxy) hexyl]-thio}-3-pyridinol Stir 300 mg. of the iodide prepared in Examples 2 or 3, 3 ml. acetonitrile 112 mg. 2-mercapto-3-pyridinol and 201 mg. cesium carbonate in a reaction flask overnight at room temperature. Remove the acetonitrile and add methylene chloride. Wash with sodium carbonate solution, water, then brine and dry over sodium sulfate. Remove the solvent then add methylene chloride, heat to dissolve the mixture, add hexane and cool to precipitate the title compound as white crystals. EXAMPLE 9 1 and 2-[6-(2-chloro-4-methoxyphenoxy)hexyl]tetrazole Stir overnight at room temperature 300 mg. of the iodide prepared in Examples 2 and 3, 3 ml. acetonitrile, 63 mg. 1-H-tetrazole and 274 mg. cesium carbonate in a reaction flask. Add an additional. 189 mg. 1-H-tetrazole and 100 mg. cesium carbonate, let stir one week at room temperature. Work up the reaction mixture in methylene chloride with a water wash. Elute on a coarse silica column with methylene chloride then ethyl acetate/methylene chloride; Isolate two fractions of the title compound, the less polar fraction and the more polar fraction. One of the fractions is the 1-substituted tetrazole and the other fraction is the 2-substituted tetrazole. EXAMPLE 10 1-[6-(2-chloro-4-methoxyphenoxy)hexyl] -1,2,3,4-tetrahydropyrlmidine-2,4-dione Stir overnight at room temperature, 300 mg. of the iodide made in Examples 2 or 3, 1 ml. acetonitrile, 274 mg. ceslum carbonate, 270 mg. of 2N-benzoyl uracil, 1 ml. of DMF (to enhance solubility) and 100 mg. additional of cesium carbonate in a reaction flask. Work up in methylene chloride with water and add methanolic potassium carbonate then again stir overnight at room temperature. Work up in methylene chloride with a water wash. Elute on a coarse silica column with methylene chloride and sequently 10%, 20%, 30% and 40% ethyl acetate/methylene chloride to obtain the title compound as an oil which crystallizes upon standing. EXAMPLE 11 1-[5-(2-chloro-4-methoxyphenoxy)pentyl]imidazole (a) Prepare 5-[2-chloro-4-methoxyphenoxy)-pentyl-1-iodide by mixing 3 gms. 2-chloro-4-methoxyphenol, 8.7 gms. 1,5-dibromo pentane, and 5.2 gms. potassium carbonate to 75 ml. acetone in a reaction flask. Purge with nitrogen, reflux for 48 hours. Add CH₂Cl₂ and wash with water, then brine and dry over sodium sulfate. Elute on a coarse silica column with hexane, 10, 15 and 20% CH₂Cl₂/hexane. Isolate product, add 50 ml. acetone, 8.5 g sodium iodide and heat to reflux 10-15 min. Remove acetone, add CH₂Cl₂ and wash with water, then brine and dry over sodium sulfate. Remove solvent and recover the product. (b) Add 350 mg. of the product of step (a) to 2 ml. DMF (dimethylformamide) and 300 mg. sodium imidazole in a reaction flask. Stir for about 24 hours. Recover the title compound by treating with methylene chloride, a water wash and brine. Dry over sodium sulfate and remove the solvent to obtain a crystalline compound. Prepare the hydrochloride salt by reacting 275 mg. of the title compound with 10.2 ml. of 0.1N HCl. methylene chloride, wash with water, then brine and recover the title compound by removing the solvent. The hydrochloride salt is made by reacting the title compound with about 1.1 eq: 0.1N HCl. EXAMPLE 12 1-[6-(2-chloro-4-methoxyphenoxy)hexyl]-2-hydroxybenzimidazole and N,N'-bis-[6-(2-chloro -4-methoxyphenoxy)hexyl]-2-benzimidazolone Stir overnight at room temperature, 1 gm. 2 hydroxybenzimidazole, 2 gms. of the iodide prepared in Examples 2 or 3, 0.35 gm sodium hydroxide and 10 ml DMF in a reaction flask. Partition with water/methylene chloride. Elute on a silica column with 100% methylene chloride, then 50/50 methylene chloride/ethylacetate. Two major fractions are obtained, NMR shows the top spot fraction to be N,N'-bis'-[6-(2-chloro-4-methoxyphenoxy)-hexyl]-2-benzimidazolone, FAB-MS: m/z 615 (M⁺) free base, H¹-NMR-200 mHz; δ H (CDCl₃), 1.35-1.65 (8H,m), 1.70-1.90 (8H,m), 3.75 (6H,s), 3.80-4.05 (8H,m), 6.7-7.2 (10H,m), and the bottom spot fraction to be 1-[6-(2-chloro-4-methoxyphenoxy)hexyl]-2-hydroxybenzimidazole. FAB-MS: m/z 375 (M⁺); Free Base, H¹-NMR-200 mHz; δ H (CDCl₃), 1.4-1.70 (4H,m), 1.7-1.9 (4H,m), 3.75 (3H,s), 3.85-4.05 (4H,m), 6.7-7.2 (7H,m). EXAMPLE 13 9-[6-(2-chloro-4-methoxyphenoxy)hexyl]purine and 7-[6-(2-chloro-4-methoxyphenoxy)hexyl]purine Stir overnight at room temperature, 300 mg. of the iodide prepared in Examples 2 and 3, 3 ml. DMF, 147 mg. purine and 49 mg. sodium hydroxide in a reaction flask. Add methylene chloride and wash with water. Elute on a coarse silica column with methylene chloride, then 2% methanol/methylene chloride, then 4 and 5% methanol/methylene chloride to obtain a major amount of the 9-substituted title compound and a minor amount of the 7-substituted title compound. The title compounds do not form water soluble salts. EXAMPLE 14 1-[7-oxy-7-(4-methoxyphenyl)heptyl]imidazole (a) Prepare 7-(4-methoxyphenyl-7-oxo)heptyl-1-bromide by stirring for one hour at room temperature, 2.16 gm anisole, 100 ml methylene chloride, 7-bromoheptanoyl chloride and aluminum chloride. Wash with water, sodium bicarbonate solution, water then brine. Dry over sodium sulfate. Elute on a coarse silica column with hexane then methylene chloride/hexane to recover the product. (b) Heat to reflux for 45 mins. 0.5 gm ofthe product of step (a), 10 ml MEK (methylethylketone) and 1.25 gm sodium iodide. Remove most of the MEK, add methylene chloride, then wash with water, followed by brine and dry over sodium sulfate to give the iodide of the compound prepared in step (a). Add 450 mg of sodium imidazole in 10 ml DMF and stir for 48 hours. Add methylene chloride, wash with water, then wash with brine and dry over sodium sulfate to yield the title compound. EXAMPLE 15 1-[7-hydroxyimino-7-(4-methoxyphenyl)heptyl] imidazole Stir overnight at room temperature 0.5 gm of the compound prepared in Example 52(b), 10 ml ethanol, 1 ml water and a large excess of hydroxyl amine·HCl and stir for 4 hours. Remove most of the ethanol by bubbling nitrogen through the reaction mixture. Adjust the pH to about 10 with 10% aqueous NaOH, add methylene chloride and wash with water, then brine and dry over sodium sulfate. Then elute on a coarse silica column with methylene chloride then 1, 2, 3 and 4% methanol/methylene chloride to give the title compound. Prepare the hydrochloride salt by reaction with 1.1 eq. of 0.1N HCl. MS: m/z 302 (M⁺) HCl salt. EXAMPLE 16 1-[6-oxy-6-(2,4-dimethoxyphenyl)hexyl]imidazole (a) Add 1.4 gm 2,4-dimethoxybenzene and 2.2 gm 1-bromohexanoyl chloride to 100 ml methylene chloride. Add 1.3 ml tin chloride and stir for 0.5 hr. Wash with water then 5% sodium bicarbonate to yield 1-[6-oxy-6-(2,4-dimethoxyphenyl)hexyl]bromide. (b) Add 2.8 gm sodium imidazole in DMF to 3 gm of the compound produced in step (a). Stir for 48 hours, remove DMF, partitition with water/methylene chloride, elute on silica column with 100% methylene chloride then 5% methanol/methylene chloride to yield the title compound. Prepare the hydrochloride salt by reaction with 0.1N HCl. EXAMPLE 17 1-[6-hydroxy-6-(2,4-dimethoxyphenyl)hexyl]imidazole Add 50 ml of ethanol to 1.3 gm of the compound prepared in Example 67, then add 0.5 gm sodium borohydride. Stir for 2.5 hours, remove the solvent, extract with methylene chloride, elute on a silica column with 100% methylene chloride, then 5% methanol/methylene chloride to yield the title compound. EXAMPLE 18 1-[6-(2,4-dimethoxyphenyl)hex-5-enyl]-imidazole, hydrochloride Treat 0.266 gm of the compound prepared in Example 68 with 11 ml of 0.1N HCl to give the title compound. EXAMPLE 19 1-[6-(naphthalene-2-oxy)hexyl]imidazole (a) Add 5 gm of beta-naphthol to 100 ml methylene chloride then add 27 ml 1,6-dibromohexane followed by 0.5 gm tetra n-butyl ammonium sulfate then 75 ml water and 25 ml of 50% sodium hydroxide. Stir for 48 hours, partition with water/methylene chloride, remove the methylene chloride and distill the residue at 0.1 mm mercury to give the product 1-[6-(naphthalene-2-oxy)hexyl]bromide. (b) Add 2 gm of the compound produced in step (a) to a solution of 2 gm imidazole and 0.5 gm sodium hydroxide in 20 ml DMF and stir overnight. Remove the solvent, partition with methylene chloride/water. Elute on a silica column with 100% methylene chloride then 5% methanol to yield the title compound. Prepare the hydrochloride salt by reaction with 0.1N HCl. EXAMPLE 20 1-[6-(4-methoxyphenylthio)hexyl]imidazole (a) Add to a reaction flask 10 gm p-mercaptoanisole, 55 ml 1,6-dibromohexane, 150 ml water, 200 ml methylene chloride, 50 ml of 50% sodium hydroxide and finally 2 gm tetra n-butylammonium sulfate and stir overnight. Partition with water/methylene chloride then brine/methylene chloride. Remove excess dibromohexane. Add the resulting residue to hexane, remove crystalline disulfide side product then remove the hexane to obtain 1-[6-(4-methoxyphenylthio)hexyl]bromide. (b) Dissolve 5 gm imidazole and 1.5 gm sodium hydroxide in DMF. Add 5 gms of the compound prepared in step (a) and stir overnight. Remove the solvent, partition with water/methylene chloride. Elute the methylene chloride. Elute the methylene chloride fraction on a silica column with 100% methylene chloride then with 5% methanol/methylene chloride to yield the title compound. Prepare the hydrochloride salt by reaction with 0.1N hydrochloric acid. EXAMPLE 21 1-[6-(4-methoxyphenylsulfonyl)hexyl]imidazole Add 3.5 gm of the title compound prepared in Example 78 to 125 ml acetic acid, then add 24 ml of 30% hydrogen peroxide in 2 portions, 24 hours apart, stir for 48 hours. Adjust pH to >10 with 25% sodium hydroxide. Partition with water/methylene chloride. Elute on a silica column using 100% methylene chloride then 5% methanol to yield the title compound. Prepare the hydrochloride salt by reaction with 0.1N hydrochloric acid.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A compound respresented by formula I Z-X-Q-Y-W I and pharmaceutically acceptable acid addition, basic addition and quarternary amine salts thereof and pharmaceutically acceptable solvates thereof, wherein Z is tetiary butyl, phenyl, naphthyl or adamantyl; substituted phenyl, wherein the substituents are one or more of halogen, C₁-C₁₀ alkoxy, phenoxy, nitrile, nitro, phenylsulfonyl, C₁-C₁₀ alkyl-sulfonyl, oxazol-2-yl, C₁-C₁₀ alkanoyl, benzoyl, C₁-C₁₀ alkoxycarbonyl, C₁-C₁₀ alkyl, C₁-C₁₀ alkylthio, phenyl, phenylaminothiocarbonyl, or C₁-C₁₀ alkylaminothiocarbonyl; 4 to 6 membered unsubstituted or substituted heterocyclic ring containing at least one nitrogen with the remaining members of the ring being at least one carbon, and optionally sulfur or oxygen, wherein the substituents are one or more of carboxyl, hydroxymethyl, C₁-C₁₀ alkyl, C₁-C₁₀ alkylcarbonyl, phenyl C₁-C₁₀ alkyl or naphthyl C₁-C₁₀ alkyl; X and Y are each independently a bond, -O-, -S-, -SO₂-, Q is a C₁-C₁₀ alkanediyl-C₄-C₇ cycloalkanediyl-C₁-C₁₀ alkanediyl, C₂-C₁₀ alkynediyl, phenylene, dihydrofurandiyl, tetrahydrofurandiyl, tetrahydropyrandiyl or, C₁-C₁₀ alkanediyltetrahydrofuranediyl-C₁-C₁₀ alkanediyl, wherein the substituents are one or more of hydroxy, epoxy, fluorine, chlorine, azide, or amino; W is a monovalent substituted or unsubstitued phenyl or naphthyl group or a heterocyclic single or fused ring containing from 4 to 10 ring atoms, at least one hetero atom of which is a nitrogen atom and the remaining ring atoms being at least one carbon and optionally sulfur or oxygen, wherein the substituents are one or more of hydroxy, oxo, amino, carbamoyl, carboxyl, nitrile, nitro, C₁-C₁₀ alkoxy carbonyl, fluorine, chlorine, iodine, sulfamyl, C₁-C₁₀ alkyl, C₁-C₁₀ alkylthio, C₁-C₁₀ alkoxy, hydroxy C₁-C₁₀ alkyl, C₁-C₁₀ alkoxycarbonyl C₁-C₁₀ alkyl, amino C₁-C₁₀ alkyl, carboxy C₁-C₁₀ alkyl, guanidino, thioureido, C₁-C₁₀ alkylsulfonyl-amino, aminocarbonyl C₁-C₁₀ alkyl, allyloxycarbonylmethyl or carbamoyloxy C₁-C₁₀ alkyl; with the proviso that W cannot be substituted or unsubstituted isoxazolyl. A compound of Claim 1 represented by the formula Z¹-X¹-Q¹-W¹ and pharmaceutically acceptable acid addition salts thereof, wherein Q¹ is alkynediyl of 6, 7 or 8 carbon atoms; or methylcyclohexylmethyl; W¹ is unsubstitued or substitued imidazol-1-yl, purin-9-yl, imidazol-2-yl, wherein said substituents are one or more of C₁-C₁₀ alkyl, hydroxy C₁-C₁₀ alkyl, nitro, C₁-C₁₀ alkoxycarbonyl, carboxymethyl or aminocarbonylmethyl; X¹ is -O-, and Z¹ is A compound of claim 1 represented by the formula Z²-X²-Q²-Y²-W² and pharmaceutically acceptable acid addition salts or quarternary amine salts thereof, wherein Z² is phenyl; substituted phenyl wherein the substituents are independently one or more of halogen, C₁-C₁₀ alkylthio, C₁-C₁₀ alkylsulfonyl, C₁-C₁₀ alkoxy, oxazol-2-yl, phenoxy; imidazo-1-yl; C₁-C₁₀ alkyl substituted imidazo-1-yl; or tert-butyl; X² is a bond, -O-, -S-, OR -SO₂- Q² is alkynediyl of 6 to 8 carbon atoms; or methylcyclohexylmethyl; Y² is a bond, -S- or -SO₂-; W² is imidazol-1-yl; substituted imidazol-1-yl wherein the substituents are independently one or more of C₁-C₁₀ alkyl, hydroxyl C₁-C₁₀ alkyl, amino C₁-C₁₀ alkyl or C₁-C₁₀ alkoxycarbonyl; imidazol-2-yl, imidazol-4-yl; imidazol-5-yl; substituted imidazol-2-yl, -4-yl or -5-yl, wherein the substituents are independently one or more of C₁-C₁₀ alkyl or alkyloxycarbonyl methyl; pyrrolidin-1-yl; benzimidazol-1-yl; 1,4-dihydro-4-oxo-7-methyl-1,8-3-carboxyl-purin-9-yl; pyridin-2-yl; pyrazol-1-yl; or benzimidazol-2-yl. A compound of claim 1 selected from the group consisting of: trans 1-[(2-chloro-4-methoxyphenoxy)methyl]4-[(1-imidazolyl)methyl]cyclohexane; 1-(9,9-dimethyl-dec-7-ynyl)-imidazole; 1-[6-(2-chloro-4-methoxyphenoxy)-hex-2-ynyl]imidazole; 1-(8-phenyl-oct-7-ynyl)imidazole; The use of a compound of formula I as defined in any one of claims 1 to 4 for preparing a pharmaceutical composition. A compound of formula I according to any of claims 1-4 for use as an active pharmaceutical substance. A process for producing a compound of formula I as defined in claim 1 characterized in that either: (A) to produce a compound of formula I, a compound of the formula Z-X-Q'-L¹ wherein Z and X are as defined in claim 1, Q' is the same as Q defined in claim 1, or, provided Q in formula I is to contain at least one of the groups wherein each R is independently hydrogen or C₁-C₁₀ alkyl, Q' may also be the same as Q defined in claim 1 minus at least one of the groups and L¹ is a leaving group, with a compound having the formula L²-Y'-W'' wherein L² is a leaving group, W'' is as defined for W in claim 1 or a tautomer thereof, and Y' is the same as Y defined in claim 1, or, provided Q in formula I is to contain at least one of the groups wherein each R is independently hydrogen or C₁-C₁₀ alkyl, Y' may also be the same as Y defined in claim 1 plus at least one of the groups or (B) to produce a compound of formula I, at least one compound of the formula Z-X-Q'-L¹ wherein Z, X, Q' and L¹ are as defined above is reacted with a compound of the formula L³-Y'-W'''-Y'-L⁴ wherein L³ and L⁴ are leaving groups, each Y' is independently as defined above, and W''' is divalent W' as defined above or (C) to produce a compound of formula I, wherein Z and W are the same and X and Y are the same, reacting a compound of the formula L²-Y'-W'' wherein Y' and W'' are as defined in previously and L¹ is a leaving group, with a compound of the formula L⁵-Q''-L⁶ wherein L⁵ and L⁶ are leaving groups and Q'' is divalent Q' as defined above, wherein in the above processes, any reactive groups are protected if necessary or desired, the above processes followed if necessary or desired by (i) removal of any protecting groups, (ii) conversion of a compound so produced to another compound of formula I or II, (iii) if more than one compound of formulas I or II is produced, separation of the compounds so produced, or (iv) conversion of any of the compounds so produced to an acid addition, basic addition, or quaternary amine salt or pharmaceutically acceptable solvate thereof. Claims for the following Contracting States : ES, GR A process for producing a compound respresented by formula I Z-X-Q-Y-W I and pharmaceutically acceptable acid addition, basic addition and quarternary amine salts thereof and pharmaceutically acceptable solvates thereof, wherein Z is tetiary butyl, phenyl, naphthyl or adamantyl; substituted phenyl, wherein the substituents are one or more of halogen, C₁-C₁₀ alkoxy, phenoxy, nitrile, nitro, phenylsulfonyl, C₁-C₁₀ alkyl-sulfonyl, oxazol-2-yl, C₁-C₁₀ alkanoyl, benzoyl, C₁-C₁₀ alkoxycarbonyl, C₁-C₁₀ alkyl, C₁-C₁₀ alkylthio, phenyl, phenylaminothiocarbonyl, or C₁-C₁₀ alkylaminothiocarbonyl; 4 to 6 membered unsubstituted or substituted heterocyclic ring containing at least one nitrogen with the remaining members of the ring being at least one carbon, and optionally sulfur or oxygen, wherein the substituents are one or more of carboxyl, hydroxymethyl, C₁-C₁₀ alkyl, C₁-C₁₀ alkylcarbonyl, phenyl C₁-C₁₀ alkyl or naphthyl C₁-C₁₀ alkyl; X and Y are each independently a bond, -O-, -S-, -SO₂-, Q is a C₁-C₁₀ alkanediyl-C₄-C₇ cycloalkanediyl-C₁-C₁₀ alkanediyl, C₂-C₁₀ alkynediyl, phenylene, dihydrofurandiyl, tetrahydrofurandiyl, tetrahydropyrandiyl or, C₁-C₁₀ alkanediyltetrahydrofuranediyl-C₁-C₁₀ alkanediyl, wherein the substituents are one or more of hydroxy, epoxy, fluorine, chlorine, azide, or amino; W is a monovalent substituted or unsubstitued phenyl or naphthyl group or a heterocyclic single or fused ring containing from 4 to 10 ring atoms, at least one hetero atom of which is a nitrogen atom and the remaining ring atoms being at least one carbon and optionally sulfur or oxygen, wherein the substituents are one or more of hydroxy, oxo, amino, carbamoyl, carboxyl, nitrile, nitro, C₁-C₁₀ alkoxy carbonyl, fluorine, chlorine, iodine, sulfamyl, C₁-C₁₀ alkyl, C₁-C₁₀ alkylthio, C₁-C₁₀ alkoxy, hydroxy C₁-C₁₀ alkyl, C₁-C₁₀ alkoxycarbonyl C₁-C₁₀ alkyl, amino C₁-C₁₀ alkyl, carboxy C₁-C₁₀ alkyl, guanidino, thioureido, C₁-C₁₀ alkylsulfonyl-amino, aminocarbonyl C₁-C₁₀ alkyl, allyloxycarbonylmethyl or carbamoyloxy C₁-C₁₀ alkyl; with the proviso that W cannot be substituted or unsubstituted isoxazolyl, characterised by (A), reacting a compound of the formula Z-X-Q'-L¹ wherein Z and X are as defined previously, Q' is the same as Q defined previously, or, provided Q in formula I is to contain at least one of the groups wherein each R is independently hydrogen or C₁-C₁₀alkyl, Q' may also be the same as Q defined previously minus at least one of the groups and L¹ is a leaving group, with a compound having the formula L²-Y'-W'' wherein L² is a leaving group, W'' is as defined for W previously or a tautomer thereof, and Y' is the same as Y defined previously, or, provided Q in formula I is to contain at least one of the groups wherein each R is independently hydrogen or C₁-C₁₀alkyl, Y' may also be the same as Y defined previously plus at least one of the groups or (B) reacting at least one compound of the formula Z-X-Q'-L¹ wherein Z, X, Q', and L¹ are as defined previously, with a compound of the formula L³-Y'-W'''-Y'-L⁴ wherein L³ and L⁴ are leaving groups, each Y' is independently as defined above, and W''' is divalent W' as defined above; or (C) to produce a compound of formula I wherein Z and W are the same and X and Y are the same, reacting a compound of the formula L²-Y'-W'' wherein Y' and W'' are as defined previously and L² is a leaving group, with a compound of the formula L⁵-Q''-L⁶ wherein L⁵ and L⁶ are leaving groups and Q'' is divalent Q' as defined above, wherein in the above processes, any reactive groups are protected if necessary or desired, the above processes followed if necessary or desired by (i) removal of any protecting groups, (ii) conversion of a compound so produced to another compound of formula I, (iii) if more than one compound of formula I is produced, separation of the compounds so produced, or (iv) conversion of any of the compounds so produced to an acid addition, basic addition, or quaternary amine salt or pharmaceutically acceptable solvate thereof. A process according to Claim 1 for producing a compound represented by the formula Z¹-X¹-Q¹-W¹ and pharmaceutically acceptable acid addition salts thereof, wherein Q¹ is alkynediyl of 6, 7 or 8 carbon atoms; or methylcyclohexylmethyl; W¹ is unsubstituted or substituted imidazol-1-yl, purin-9-yl, imidazol-2-yl, wherein said substituents are one or more of C₁-C₁₀ alkyl, hydroxy C₁-C₁₀ akyl, nitro, C₁-C₁₀ alkoxycarbonyl, carboxymethyl or aminocarbonylmethyl; X¹ is -O-, and Z¹ is A process according to claim 1 for producing a compound represented by the formula Z²-X²-Q²-Y²-W² and pharmaceutically acceptable acid addition salts or quarternary amine salts thereof, wherein Z² is phenyl; substituted phenyl wherein the substituents are independently one or more of halogen, C₁-C₁₀ alkylthio, C₁-C₁₀ alkylsulfonyl, C₁-C₁₀ alkoxy, oxazol-2-yl, phenoxy; imidazo-1-yl; C₁-C₁₀ alkyl substituted imidazo-1-yl; or tert-butyl; X² is a bond, -O-, -S-, OR -SO₂- Q² is alkynediyl of 6 to 8 carbon atoms; or methylcyclohexylmethyl; Y² is a bond, -S- or -SO₂-; W² is imidazol-1-yl; substituted imidazol-1-yl wherein the substituents are independently one or more of C₁-C₁₀ alkyl, hydroxyl C₁-C₁₀ alkyl, amino C₁-C₁₀ alkyl or C₁-C₁₀ alkoxycarbonyl; imidazol-2-yl, imidazol-4-yl; imidazol-5-yl; substituted imidazol-2-yl, -4-yl or -5-yl, wherein the substituents are independently one or more of C₁-C₁₀ alkyl or alkyloxycarbonyl methyl; pyrrolidin-1-yl; benzimidazol-1-yl; 1,4-dihydro-4-oxo-7-methyl-1,8-3-carboxyl-purin-9-yl; pyridin-2-yl; pyrazol-1-yl; or benzimidazol-2-yl. A process according to claim 1 for producing a compound selected from the group consisting of: trans 1-[(2-chloro-4-methoxyphenoxy)hexyl]-4,5-[(1-imidazolyl)methyl]cyclohexane; 1-(9,9-dimethyl-dec-7-ynyl)-imidazole 1-[6-(2-chloro-4-methoxyphenoxy)-hex-2-ynyl]imidazole; 1-(8-phenyl-oct-7-ynyl)imidazole; The use of a compound of formula I as defined in any one of claims 1 to 4 for preparing a pharmaceutical composition.

Inventors: GANGULY ASHIT KUMAR, GIRIJAVALLABHAN VIYYOOR MOOPIL, PINTO PATRICK ANTHONY, VERSACE RICHARD WILLIAM, GANGULY, ASHIT KUMAR, GIRIJAVALLABHAN, VIYYOOR MOOPIL, PINTO, PATRICK ANTHONY, VERSACE, RICHARD WILLIAM
Applicants: SCHERING CORP, SCHERING CORPORATION
Application year: 1987
Main classification: C07D233
IPC codes: C07D239, C07D295, C07D257, C07D235, C07D405, C07D249, C07D213, A61K31, C07C67, C07C313, C07D263, C07C317, A61P29, C07D413, C07D473, C07D233, C07C49, C07D521, A61P31, C07D493, C07D277, C07D471, C07C323, A61P7, C07D487, C07C45